Research Activities

2019

 

 

A phase 3 randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and a safety of pimodivir in combination with the standard-of-care treatment in adolescent, adult, and elderly non-hospitalized subjects with influenza A infection who are at risk of developing complications (FLZ3002)

 

2018

 

 

Antibody persistence at 3 years after a single dose vaccination of acellular pertussis vaccines containing genetically-detoxified pertussis toxin

 

2018

 

 

HPV Vaccine effectiveness after 5 years of vaccination

 

2018

 

 

A randomized, observer-blind, active comparator controlled, multicenter, phase 3 study to assess the efficacy, safety, and immunogenicity of a plant-derived Quadrivalent VLP influenza vaccine in adults 65 years of age and older

 

2017

 

 

A randomized, observer-blind, placebo-controlled, multicenter, phase 3 study to assess the efficacy, safety, and immunogenicity of a Plant-derived Quadrivalent VLP influenza vaccine in adults 18-64 years of age

 

2017

 

 

A Phase 1/2a Study to evaluate the safety/tolerability and immunogenicity of homologous Ad26 mosaic vector vaccine regimens or Ad26 mosaic and MVA mosaic heterologous vector vaccine regimens, with high-dose, low-dose or no clade C gp140 protein plus adjuvant for HIV prevention

 

2017

 

 

A phase II/III double blinded, randomized controlled, non-inferiority trial to evaluate the safety and immunogenicity of Tri fluvac, a seasonal trivalent inactivated split virion influenza vaccine, in healthy THAI subjects aged 18-49 years

 

2017

 

 

Medical and economic burden of healthcare services for immigrants at Phaholpolpayuhasena hospital, Kanchanaburi

 

2017

 

 

Antibody persistence at 2 years after a single dose vaccination of acellular pertussis vaccines among Thai adolescents

 

2015

 

 

A phase II/III randomized, observer-blind, controlled study to demonstrate non-inferior immunogenicity of a combined Tetanus-diphtheria-acellular Pertussis vaccine as compared to Adacel® vaccine in healthy subjects aged 12-17 years.

 

2015

 

 

A Phase 1/2 Randomized Double Blind Control Study to Evaluate the Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Split Virion Influenza Vaccine in Healthy Thai Adults Aged Between 18 years to 49 years and Adolescents Aged Between 12 years to <18 years.

 

2015

 

 

Recombinant ALVAC-HIV (vCP1521) and Global Solutions for Infectious Diseases (GSID) gp120 B/E (AIDSVAX® B/E) formulated in L(MPLA) and alum in a Prime-Boost Regimen in HIV-uninfected Adults in Thailand, Uganda and Mozambique

 

2015

 

 

A phase 1/2a study to evaluate the safety/tolerability and immunogenicity of homologous Ad26 Mosaic vector vaccine regimens or Ad26 Mosaic and MVA Mosaic heterologous vector vaccine regimens, with high-dose, low-dose or no Clade C gp140 protein plus adjuvant for HIV prevention

 

2014

 

 

Evaluation of Priming effects by Pandemic Live Attenuated Influenza Vaccine (LAIV candidate vaccine strain A/17/turkey/Turkey/05/133 (H5N2)) on the Subsequent Response to Inactivated H5N1 Vaccine in Healthy Thai Volunteers: A Non-Randomized, Open Label Study

 

2014

 

 

 

A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in Preadolescents and Adolescents (9 to 14 year olds) with a Comparison to Young Women (16 to 26 year olds) who receive 3-dose regimen

 

2013

 

 

Acceptability of an influenza vaccine among the elderly in Bangkok and surrounding provinces, Thailand

 

2013

 

 

Community Engagement Program to Assess and Prepare Muang District Community in Nakhon Phanom Province for Participation in a Phase III Government Pharmaceutical Organization (GPO) Seasonal Trivalent Live Attenuated Influenza Vaccine Trial

 

2012

 

Capability Assessment for Supporting Research and Development of Vaccine in Thailand

 

2012

 

 

Randomized Double-Blind Placebo Controlled Phase III Trial to Assess the Clinical Efficacy and Safety of Government Pharmaceutical Organization (GPO) Seasonal Trivalent Live Attenuated Influenza Vaccine among Children Aged 2-18 Years

 

2012-2013

 

Phase I safety and immunogenicity of live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 (H5N2) in healthy Thai volunteers

 

2012-ongoing

 

 

Randomized,Double Blind Evaluation of Different One-Year Boosts after Sanofi Pasteur Live Recombinant ALVAC-HIV (vCP1521) and Global Solutions for Infectious Diseases (GSID) gp120 B/E (AIDSVAX® B/E) Prime-Boost Regimen in HIV-uninfected Thai Adults

 

2011-ongoing

 

 

Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Participants in the HIV Vaccine Efficacy Trial RV144: “Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming with VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults

 

2011-ongoing

 

 

Efficacy and safety of a novel Tetravalent Dengue vaccine in healthy children aged 2 to 14 years in Asia

 

2010

 

Safety, Immunogenity and Efficacy Studies of WRSS1, a Live Attenuated Shigella sonnei Vaccine Candidate, in Healthy Thai Adults

 

2010-2011

 

Prospective surveillance of febrile illness for dengue-endemic areas in Asia

 

2009-2011

 

 

Phase I/II safety and immunogenicity of pandemic live attenuated influenza vaccine (PLAIV) candidate strain A/17/CA/2009/38 (H1N1) in healthy Thais

 

2009-ogoing

 

 

 

A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 year olds) with a Comparison to Young Women (16 to 26 year olds)

 

2008-2009

 

A bioequivalence study of two formulations of 16 mg Candesartan tablets in healthy Thai volunteers

 

2008-2009

 

Measurement of Anogenital Wart Burden and Cost of Illnesses in Thailand

 

2008-2009

 

 

A Phase 2b/3, randomized, double blind, dose confirming study of the safety, efficacy and tolerability of apricitabine versus lamivudine in treatment-experienced HIV-1 infected patients with the M184V mutation in reverse transcriptase.

 

2007-2009

 

Measuring Herpes Zoster and Post-Herpetic Neuralgia Associated Burden of Illness and Health Care Utilcation and Costs in Thailand

 

2007-2009

 

Assessing the psychosocial burden in women with an abnormal pap results after screening interventions.

 

2006

 

Establishment of a Shigella sonnei Challenge Model for Evaluation of Future Vaccine Candidates

 

2005-2009

 

 

A study to evaluate the efficacy of GARDASILTM (Human Papillomavirus [types 6,11,16,18] recombinanat vaccine) in reducing the incidence of HPV 6-,11-,16-, and 18- related CIN, AIS, and cervical cancer, and HPV 6-,11-,16-, and 18-related external genital warts, VIN, VaIN, vulvar cancer, and vaginal cancer in 26- to- 45 year-old women

 

2003-2006

 

A cross-sectional study to screen for and generate broady neutralizing monoclonal antibodies from HIV infected individuals.

 

2009-2010

 

 

Phase III HIV – 1 Preventive Vaccine Trial, “A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC- HIV (vCP 1521) Priming with Vaxgen gp120 B/E (AIDSVAX® B/E) Boosting in HIV- un infected Thai Adults”.

 

2002-2008

 

A World-wide Phase I, Dose-escalating Study of the Safety, Tolerability and Immunogenicity of a 3-Dose Regimen of the MRKAd 5 HIV-1 gag Vaccine in healthy adults.

 

2002-2007

 

 

A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASILTM, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16-to-26-Year-Old Women

 

2001-2003

 

Safety and Therapeutic Effects of Jin Huang Chinese Medicine in Uncomplicated HIV – 1 Patients.

 

2001-2002

 

Open-Label, Treatment Protocol for the Safety and Efficacy of SCH 56592 (Oral Suspension) in the Treatment of Invasive Fungal Infections

 

2001-2002

 

Observational Probe Study of In Vitro Immune Response Parameters to Candidate HIV – 1 Vaccine Antigens among Subjects in Thailand.

 

2001-2002

 

A Retrospective Study to Establish a Historical Database on the Efficacy of Standard Antifungal Therapy in Patients with Invasive Fungal Infection.

 

2000-2004

 

A Phase III Trial to Determine the Efficacy of AIDSVAXTM B/E Vaccine in IVDUs in Bangkok, Thailand.

 

2000-2003

 

 

A multicenter, randomized, double-blind, phase II study to evaluate the safety, tolerance and efficacy of multiple doses of SCH 56592 versus fluconazole in the treatment of oropharyngeal candidiasis (OPC) in HIV-positive patients

 

2000-2002

 

Phase I/II trial of Pasteur Merieux Connaught (PMC) live recombinant ALVAC – HIV (vCP1521) Priming with Vaxgen gp 120 B/E (AIDSV AXTM B/E) Boost in Thai HIV – Seronegative Adults

 

1999-2000

 

Cholera Challenge in volunteers using frozen V. cholera 0139 bacteria for challenge

 

1998-2000

 

 

A Phase I/II Double-blind, Placebo-controlled study of the Chiron Biocine HIV Thai E gp 120/MF 59 Vaccine Administered alone or combined with The Chiron Biocine HIV SF 2 gp 120 Antigen in healthy HIV-seronegative Thai Adults.

 

Last updated: June 06, 2020